Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin

Diagnostic Microbiology and Infectious Disease

Volumn 82, Issue 1, 2015, Pages 73-77

  Jones, Ronald N ^a   Farrell, David J ^a   Flamm, Robert K ^a   Sader, Helio S ^a   Dunne, Michael W ^b   Mendes, Rodrigo E ^a  

^a JMI LABORATORIES   (United States)

^b Durata Therapeutics   (United States)

Author keywords

Dalbavancin; Surrogate marker; Susceptibility testing

Indexed keywords

DALBAVANCIN; ORITAVANCIN; POLYSORBATE; TELAVANCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; TEICOPLANIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DRUG HALF LIFE; ENTEROCOCCUS; EUROPE; FOOD AND DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS PYOGENES; UNITED STATES; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GRAM POSITIVE INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; BIOMARKERS; ENTEROCOCCUS; EUROPE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS; STREPTOCOCCUS; TEICOPLANIN; UNITED STATES; VANCOMYCIN;

EID: 84928353476     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2015.01.017     Document Type: Article

References (27)

1. Anderegg T.R., Biedenbach D.J., Jones R.N. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity. J Clin Microbiol 2003, 41:2795-2796.
2. Andes D., Craig W.A. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007, 51:1633-1642.
3. Biedenbach D.J., Bell J.M., Sader H.S., Turnidge J.D., Jones R.N. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother 2009, 53:1260-1263.
4. Billeter M., Zervos M.J., Chen A.Y., Dalovisio J.R., Kurukularatne C. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 2008, 46:577-583.
5. Boucher H.W., Wilcox M., Talbot G.H., Puttagunta S., Das A.F., Dunne M.W. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014, 370:2169-2179.
6. Chambers H.F. Pharmacology and the treatment of complicated skin and skin-structure infections. N Engl J Med 2014, 370:2238-2239.
7. Clinical and Laboratory Standards Institute (CLSI) M23-A3. Development of in vitro susceptibility testing criteria and quality control parameters 2008, CLSI, Wayne, PA. 3rd ed.
8. Clinical and Laboratory Standards Institute (CLSI) M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2012, CLSI, Wayne, PA. 9th ed.
9. Clinical and Laboratory Standards Institute (CLSI) M100-S24. Performance standards for antimicrobial susceptibility testing: 24th informational supplement 2014, CLSI, Wayne, PA.
10. Dalvance™ Package Insert 2014, DurataTherapeutics Intl, Chicago, IL, USA, (Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021883s000lbl.pdf. Accessed July 2014).
11. Dorr M.B., Jabes D., Cavaleri M., Dowell J., Mosconi G., Malabarba A., et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005, 55(Suppl. 2):ii25-ii30.
12. Fritsche T.R., Rennie R.P., Goldstein B.P., Jones R.N. Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms. J Clin Microbiol 2006, 44:2988-2990.
13. Jauregui L.E., Babazadeh S., Seltzer E., Goldberg L., Krievins D., Frederick M., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005, 41:1407-1415.
14. Jones R.N., Pfaller M.A. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from The SENTRY Antimicrobial Surveillance Program (1997-1999). Diagn Microbiol Infect Dis 2001, 39:237-243.
15. Jones R.N., Streit J.M., Fritsche T.R. Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int J Antimicrob Agents 2004, 23:197-199.
16. Jones R.N., Fritsche T.R., Sader H.S., Goldstein B.P. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother 2005, 17:593-600.
17. Jones R.N., Sader H.S., Fritsche T.R., Hogan P.A., Sheehan D.J. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J Clin Microbiol 2006, 44:2622-2625.
18. Jones R.N., Sader H.S., Fritsche T.R., Janechek M.J. Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagn Microbiol Infect Dis 2007, 59:467-472.
19. Jones R.N., Flamm R.K., Sader H.S. Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn Microbiol Infect Dis 2013, 76:122-123.
20. Jones R.N., Flamm R.K., Sader H.S., Stilwell M.G. Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically-indicated species. Diagn Microbiol Infect Dis 2013, 75:89-93.
21. Jones R.N., Sader H.S., Flamm R.K. Update of dalbavancin spectrum and potency in the USA; report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 2013, 75:304-307.
22. Lin G., Smith K., Ednie L.M., Appelbaum P.C. Antipneumococcal activity of dalbavancin compared to other agents. Antimicrob Agents Chemother 2005, 49:5182-5184.
23. Rennie R.P., Koeth L., Jones R.N., Fritsche T.R., Knapp C.C., Killian S.B., et al. Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent. J Clin Microbiol 2007, 45:3151-3154.
24. Seltzer E., Dorr M.B., Goldstein B.P., Perry M., Dowell J.A., Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003, 37:1298-1303.
25. Streit J.M., Fritsche T.R., Sader H.S., Jones R.N. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004, 48:137-143.
26. Turnidge J., Kahlmeter G., Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 2006, 12:418-425.
27. Zhanel G.G., Calic D., Schweizer F., Zelenitsky S., Adam H., Lagace-Wiens P.R., et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010, 70:859-886.